Revolution Medicines (NASDAQ:RVMD) Reaches New 12-Month High After Analyst Upgrade

Revolution Medicines, Inc. (NASDAQ:RVMD) shares reached a new 52-week high during mid-day trading on Thursday after Wedbush raised their price target on the stock from $201.00 to $225.00. Wedbush currently has an outperform rating on the stock. Revolution Medicines traded as high as $224.24 and last traded at $221.3210, with a volume of 476250 shares traded. The stock had previously closed at $215.44.

Several other research analysts have also weighed in on the company. Royal Bank Of Canada boosted their price target on Revolution Medicines from $182.00 to $203.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Guggenheim increased their price objective on Revolution Medicines from $235.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Sanford C. Bernstein raised their target price on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research note on Friday, August 21st. Truist Financial boosted their target price on shares of Revolution Medicines from $231.00 to $239.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Piper Sandler upped their price target on shares of Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Revolution Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $179.39.

Insider Transactions at Revolution Medicines

In other news, CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the completion of the transaction, the chief financial officer directly owned 123,269 shares in the company, valued at approximately $20,749,870.77. The trade was a 13.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sushil Patel sold 5,580 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $187.99, for a total value of $1,048,984.20. Following the transaction, the director directly owned 21,656 shares in the company, valued at $4,071,111.44. The trade was a 20.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 212,497 shares of company stock valued at $38,206,486. Company insiders own 7.60% of the company’s stock.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approves RASONQUE: The FDA approved RASONQUE (daraxonrasib), Revolution Medicines’ oral RAS-targeted therapy, for adults with previously treated metastatic pancreatic ductal adenocarcinoma or patients unable to receive combination chemotherapy. The company describes it as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, creating a significant commercial opportunity in a disease with limited treatment options. FDA approval announcement
• Positive Sentiment: Commercial launch and pricing established: Revolution Medicines priced RASONQUE at approximately $39,800 per month, providing investors with an initial benchmark for potential sales and reimbursement economics. Rapid FDA approval also shortens the path from clinical development to revenue generation. RASONQUE pricing article
• Positive Sentiment: Analyst support increased: TD Cowen upgraded RVMD, adding to an already favorable analyst backdrop. Recent firms including Oppenheimer, Truist Financial, RBC and Needham have maintained Buy or Outperform ratings and raised price targets, reinforcing confidence in the drug’s launch and broader RAS-inhibitor pipeline. TD Cowen upgrade
• Neutral Sentiment: Stock already reflects substantial optimism: RVMD has risen sharply over the past year and is trading close to its $220.34 12-month high, with a market capitalization of about $46 billion. Investors may therefore demand strong launch execution and sales growth to justify the current valuation.
• Negative Sentiment: High price could weigh on adoption: The nearly $40,000 monthly list price has prompted concerns that payer negotiations, reimbursement hurdles or affordability issues could slow uptake, which may explain why investor enthusiasm has been more measured despite the approval. Drug pricing concerns
• Negative Sentiment: Insider selling: Director Mark Goldsmith sold 80,000 shares for approximately $16.7 million, reducing his holdings by about 23%. The sale does not change the company’s fundamentals but may create a modest sentiment overhang, particularly after the stock’s substantial advance. Insider sale report

Hedge Funds Weigh In On Revolution Medicines

Several institutional investors and hedge funds have recently modified their holdings of RVMD. Nextech Invest Ltd. grew its stake in Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after buying an additional 1,304,347 shares during the last quarter. Millennium Management LLC lifted its position in Revolution Medicines by 681.8% during the first quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock worth $5,529,000 after acquiring an additional 136,353 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Revolution Medicines by 14.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock worth $10,615,000 after acquiring an additional 37,345 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Revolution Medicines by 19.3% during the second quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock worth $8,352,000 after acquiring an additional 36,760 shares during the period. Finally, Jump Financial LLC boosted its holdings in shares of Revolution Medicines by 87.9% during the second quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock worth $561,000 after acquiring an additional 7,137 shares during the period. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Stock Up 2.4%

The company has a market cap of $47.29 billion, a price-to-earnings ratio of -25.05 and a beta of 1.39. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The firm has a 50-day moving average price of $191.27 and a 200 day moving average price of $147.30.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period last year, the business earned ($1.31) earnings per share. Sell-side analysts predict that Revolution Medicines, Inc. will post -8.82 EPS for the current year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.